Objective
Osteoarthritis (OA) is an incurable disease that has evaded pharmacological interference, biologic therapy or surgical intervention to prevent disease progression. Currently, OA is designated the 11th highest contributor (of 291 diseases) of global disability. In the absence of effective treatment options, cellular therapies using mesenchymal stem/stromal cells (MSCs) have emerged as potential candidates to overcome this clinical short-coming. Autologous adipose-derived mesenchymal stromal cells (ASCs) are attractive for cellular therapy given the abundance of tissue, high frequency of MSCs and minimally invasive harvest procedure. The EU consortium ADIPOA has shown in a ‘first in man’ 2-centre Phase I safety study that intraarticular injection of a single dose of autologous ASCs to the knee (18 patients, 12 month follow-up) was well-tolerated, had no adverse effects, and resulted in an improvement in pain score and functional outcome.
ADIPOA2 will deliver a large-scale clinical trial in regenerative medicine for OA. The purpose of the project is to design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) ACSs in the treatment of advanced OA of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipoaspiration.
ADIPOA2 will comprise a multi-centre, randomized clinical trial comparing culture-expanded, autologous adult ASCs in subjects with knee OA with another widely used therapeutic approach for knee degeneration (injection of Hyaluronan). There are two large elements of the study: (1) the production of consistent batches of high-quality autologous ASCs under GMP-compliant conditions and (2) delivery of these cell doses to patients in a trial which will meet all national and European regulatory and ethical standards and which will have sufficient statistical power to provide an unambiguous and definitive assessment of safety and efficacy.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
H91 Galway
Ireland
See on map
Participants (20)
40136 Bologna
See on map
93210 La Plaine Saint Denis
See on map
75654 Paris
See on map
75014 Paris
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
Participation ended
00161 Roma
See on map
D-19061 SCHWERIN
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
6525 XZ Nijmegen
See on map
Participation ended
Dublin 9 Dublin 9
See on map
35122 Padova
See on map
13589 Berlin
See on map
A94 K542 Blackrock
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
75794 Paris
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
31062 Toulouse Cedex 9
See on map
89081 Ulm
See on map
34000 Montpellier
See on map
CB2 0QQ Cambridge
See on map
41037 Mirandola
See on map
75012 Paris
See on map
31052 Toulouse Cedex 3
See on map
38700 La Tronche
See on map